- RARE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-8 Filing
Ultragenyx Pharmaceutical (RARE) S-8Registration of securities for employees
Filed: 8 Jun 23, 4:33pm
Exhibit 107.1
Calculation of Filing Fee Tables
FORM S-8
(Form Type)
ULTRAGENYX PHARMACEUTICAL INC.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Class Title (1) | Fee Calculation Rule | Amount Registered | Proposed Maximum | Maximum | Fee Rate | Amount of |
Equity | Common stock, $0.001 par value per share | Rule 457(c) and Rule 457(h) (2) | 4,500,000 (3) | $50.69 | $228,105,000 | $110.20 per $1,000,000 | $25,137.17 |
Equity | Common stock, $0.001 par value per share | Rule 457(c) and Rule 457(h) (4) | 1,400,000 (5) | $43.09 | $60,326,000 | $110.20 per $1,000,000 | $6,647.93 |
Equity | Common stock, $0.001 par value per share | Rule 457(c) and Rule 457(h) (2) | 350,000 (6) | $50.69 | $17,741,500 | $110.20 per $1,000,000 | $1,955.11 |
Total Offering Amounts |
| $306,172,500 |
| $33,740.21 | |||
Total Fee Offsets |
|
|
| — | |||
Net Fee Due |
|
|
| $33,740.21 |
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) shall also cover any additional shares of common stock, par value $0.001 per share (the “Common Stock”) of Ultragenyx Pharmaceutical Inc. that become issuable under the Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan (the “2023 Plan”), the Amended and Restated Ultragenyx Pharmaceutical Inc. 2014 Employee Stock Purchase Plan (as amended and restated, the “ESPP”), and the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan, as amended (the “Inducement Plan”), to prevent dilution in the event of stock splits, stock dividends or similar transactions.
(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on June 2, 2023.
(3) Represents 4,500,000 shares of Common Stock reserved for issuance under the 2023 Plan.
(4) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on 85% of the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on June 2, 2023. Pursuant to the ESPP, the purchase price of a share of Common Stock is 85% of the fair market value of the Common Stock.
(5) Represents the additional 1,400,000 shares of Common Stock reserved for issuance under the ESPP.
(6) Represents the additional 350,000 shares of Common Stock reserved for issuance under the Inducement Plan.